Stichting Health Action International

Tweet this page
<
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
>
Registration as it was on 13 May 2022
How to read and use this data card.
Download this datacard

Overview

Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.

Lobbying Costs

None declared

Financial year: Jan 2021 - Dec 2021

Lobbyists (Full time equivalent)

2.75 Fte (5)

Lobbyists with EP accreditation

2

High-level Commission meetings

5

Lobbying Costs over the years

  • Info

    Stichting Health Action International   (HAI)

    EU Transparency Register

    44361352681-84 First registered on 30 Nov 2009

    Goals / Remit

    Health Action International is a non-profit, independent global network of consumer groups, public interest NGOs, healthcare professionals, academics, and individuals working and interested on pharmaceutical policy issues. HAI’s mission is to increase access to essential medicines and improve their rational use through research excellence and evidence-based advocacy.

    In Europe, HAI has grown to become a pre-eminent voice in medicines policy intervention/discussion, supported by a strong European network of approximately >125 individual and organisation members from 19 European Union (EU) Member States and 14 other non-EU countries. The HAI Europe projects team, based in Amsterdam, is responsible for coordinating the work programme and related activities within the European region. HAI monitors and advocates on EU policies that affect medicines on three key thematic priorities: Access to Needed Medicines, the Rational Use of Medicines, and the Democratisation of Medicines Policy.

    Main EU files targeted

    HAI advocates for policy initiatives that help to address current shortfalls/shortcomings on access to medicines. In Europe, HAI monitors EU policy initiatives and developments with an impact on access to medicines, their rational use and on the democratisation of medicines policy. Where needed, we issue recommendations for improvement on specific topics. EU legislation, policies and initiatives of particular interest include: implementation of proposals on EU cooperation on Health Technology Assessment and clinical trials regulation; discussion of European Pharmaceutical Strategy and review of EU pharmaceutical legislation, and orphan designation and other IP incentives; EU IP Action Plan and enforcement strategy, including revision of Supplementary Protection Certificate Regulation; Competition policy; EU trade agreements with impact on access to medicines; Innovative Medicines Initiative and Horizon Europe; Multiannual Financial Framework (MFF); implementation of the One Health Action Plan against AMR; European Medicine Agency (EMA)'s policies and activities; tackling medicines shortages. HAI also advocates for stricter regulations on pharmaceutical promotion in Europe especially among healthcare professionals and students.
    In response to the Covid-19 crisis HAI has been advocating for timely access to affordable vaccines, therapeutics and diagnostics across the EU, transparency in negotiations between governments, the European Commission and pharmaceutical companies, and has been working to support the consolidation and use of the WHO Covid-19 Technologies Access Pool (C-TAP). We expect this work to continue during 2022.

    Address

    Head Office
    Overtoom, 60/II
    Amsterdam 1054HK
    NETHERLANDS
    EU Office
    Overtoom, 60/II
    Amsterdam 1054HK
    NETHERLANDS

    Website

  • People

    Total lobbyists declared

    5

    Employment timeLobbyists
    100%1
    75%1
    50%1
    25%2

    Lobbyists (Full time equivalent)

    2.75

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    2 accreditations were / are live (in bold) for the selected state of 27 Nov 2022

    Name Start date End Date
    Mr Jaume VIDAL 04 Nov 2022 03 Nov 2023
    Ms Ellie WHITE 27 Oct 2021 11 Feb 2022
    Mr Jaume VIDAL 27 Oct 2021 26 Oct 2022
    Mr Jaume VIDAL 19 Sep 2019 18 Sep 2020
    Ms Ellie WHITE 14 Sep 2019 11 Sep 2020
    Ms Ancel·la Santos Quintano 13 Oct 2018 31 Oct 2019
    Mr Jaume VIDAL 13 Oct 2018 31 Oct 2019
    Ms Ancel·la Santos Quintano 14 Oct 2017 12 Oct 2018
    Mr Jaume VIDAL 20 Jul 2017 06 Jul 2018
    Ms Tessel Mellema 07 Sep 2016 06 Sep 2017
    Ms Ancel·la Santos Quintano 07 Sep 2016 06 Sep 2017
    Ms Tessel Mellema 27 Aug 2015 26 Aug 2016
    Ms Ancel·la Santos Quintano 27 Aug 2015 26 Aug 2016
    Ms Aliénor Devalière 27 Aug 2015 26 Aug 2016
    Ms Ancel·la Santos Quintano 01 May 2014 29 Apr 2015
    Ms Aliénor Devalière 07 Jun 2014 05 Jun 2015
    Mrs Aliénor Devalière 07 Jun 2014 05 Jun 2015
    Ms Tessel Mellema 01 May 2014 28 Apr 2015
    Mrs Ancel·la Santos Quintano 01 May 2014 29 Apr 2015
    Ms Tessel Mellema 25 Jun 2013 20 Jun 2014
    Mrs Ancel·la Santos Quintano 30 May 2013 28 May 2014
    Ms Katrina Perehudoff 22 Sep 2012 26 Jun 2013
    Ms Tessel Mellema 20 Sep 2012 26 Jun 2013

    Complementary Information

    HAI has one full-time policy advisor that is solely focused on our EU projects. He is supported by Admin, Communications, PME & our Executive Director.

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Non-governmental organisations, platforms and networks and similar

  • Networking

    Affiliation

    HAI is a member of the European Public Health Alliance (EPHA), the International Society of Drug Bulletins (ISDB), the Transatlantic Consumer Dialogue (TACD), the Medicines in Europe Forum (MiEF), the European Alliance for Responsible R&D and Affordable Medicines, the Antimicrobial Resistance Coalition, and Global Snakebite Initiative. In addition, HAI enters into strategic partnership with other associations when collaborating on certain topics thus tapping into extended expertise as required.

    HAI is also a member of the EMA’s Patients and Consumers Working Party (PCWP), the HTA Network Stakeholder Pool and co-chair of European Parliament Working Group on Access to Medicines.

    HAI is in official relations with the WHO and collaborates with the organisation on several projects as well as attending governing bodies and ad-hoc meetings

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Does not represent commercial interests

    Closed financial year

    Jan 2021 - Dec 2021

    Lobbying costs for closed financial year

    Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.

    Total organisational budget in closed year

    1,946,396€

    Major funding types in closed year

    Public financing, EU funding, Member's contribution, Grants

    Major contributions in closed year

    TypeNameAmount
    Contribution Helmsley Charitable Trust 930,712€
    Contribution European Commission/HADEA 213,692€
    Grant European Commission/HADEA 213,692€

    Other financial info

    N/A

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    Artificial intelligence and digital

    Other activities

    HAI is a member of the European Medicines Agency Patients' and Consumers' Working Party (PCWP); and a member of the HTA Network Stakeholder Pool.

  • Meetings

    Meetings

    5 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't publish information about such meetings. All information below comes from European Commission web pages.

Download this datacard